Literature DB >> 17653812

Histological, CT, and intraoperative ultrasound appearance of hepatic tumors previously treated by laparoscopic radiofrequency ablation.

T Mason1, E Berber, J C Graybill, A Siperstein.   

Abstract

PURPOSE: The purpose of this paper is to compare intraoperative biopsy results of previously ablated liver tumors with their preoperative computed tomography (CT) and intraoperative laparoscopic ultrasound (LUS) appearances in patients undergoing repeat radiofrequency ablation (RFA).
METHODS: Seventy repeat RFA procedures were performed in 59 (13%) patients. Laparoscopically, suspected recurrent and stable appearing foci were biopsied using an 18 G biopsy gun. Preoperative CT and LUS appearances of the previously ablated lesions were compared with core biopsy results.
RESULTS: There were 33 patients with colorectal cancer, 11 with hepatocellular cancer, 8 with neuroendocrine tumors, and 7 with other tumor types. Two hundred lesions were treated by RFA in these 70 repeat ablations. Suspected recurrent tumor foci were enhanced on CT and produced a more finely stippled echo pattern on LUS. Biopsy confirmed recurrent tumor in 72 of 84 such lesions. Previously ablated foci had a CT appearance of a hypodense, nonenhancing lesion without evidence of adjacent enhancing foci. Laparoscopic ultrasound appearance was of a hypoechoic lesion with a coarse internal pattern with the tracks of the ablation catheter probes often still visible. Biopsy found necrotic tissue in 21 of 22 such lesions appearing radiologically to be without recurrence. Biopsy of an ablated focus adjacent to an area of suspected recurrence showed necrotic tissue in 17 of 22 lesions and viable cancer in 5.
CONCLUSION: CT and LUS appearance of previously ablated foci showed good correlation with core biopsies. CT scan is reliable in following RFA lesions, without the need for routine biopsy. LUS reliably distinguished recurrent from ablated lesions in patients undergoing repeat ablation.

Entities:  

Mesh:

Year:  2007        PMID: 17653812     DOI: 10.1007/s11605-007-0214-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

Review 1.  Interstitial therapies for liver tumors.

Authors:  T S Ravikumar
Journal:  Surg Oncol Clin N Am       Date:  1996-04       Impact factor: 3.495

2.  The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.

Authors:  S Bengmark; L Hafström
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

Review 3.  Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

Authors:  S Faiss; H Scherübl; E O Riecken; B Wiedenmann
Journal:  Recent Results Cancer Res       Date:  1996

4.  Laparoscopic radiofrequency ablation of primary and metastatic liver tumors. Technical considerations.

Authors:  A Siperstein; A Garland; K Engle; S Rogers; E Berber; A String; A Foroutani; T Ryan
Journal:  Surg Endosc       Date:  2000-04       Impact factor: 4.584

5.  Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes.

Authors:  E Berber; E Ari; N Herceg; A Siperstein
Journal:  Surg Endosc       Date:  2005-10-24       Impact factor: 4.584

6.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.

Authors:  Eren Berber; Nora Flesher; Allan E Siperstein
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

7.  Cytoreductive hepatic surgery for neuroendocrine tumors.

Authors:  G P McEntee; D M Nagorney; L K Kvols; C G Moertel; C S Grant
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

8.  CT of the liver after cryotherapy of hepatic metastases: imaging findings.

Authors:  R F McLoughlin; J F Saliken; G McKinnon; D Wiseman; W Temple
Journal:  AJR Am J Roentgenol       Date:  1995-08       Impact factor: 3.959

9.  Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.

Authors:  M di Bartolomeo; E Bajetta; R Buzzoni; L Mariani; C Carnaghi; L Somma; N Zilembo; A di Leo
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  3 in total

Review 1.  Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy.

Authors:  Ping Liang; Jie Yu; Ming-De Lu; Bao-Wei Dong; Xiao-Ling Yu; Xiao-Dong Zhou; Bing Hu; Ming-Xing Xie; Wen Cheng; Wen He; Jian-Wen Jia; Guo-Rong Lu
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Chronological changes of radiofrequency ablation zone in rabbit liver: an in vivo correlation between gross pathology and histopathology.

Authors:  Kyoung D Song; Min Woo Lee; Hyunchul Rhim; Tae Wook Kang; Dong Ik Cha; Jehoon Yang
Journal:  Br J Radiol       Date:  2017-01-31       Impact factor: 3.039

3.  Treatment of malignant liver tumors by radiofrequency ablation combined with low-frequency ultrasound radiation with microbubbles.

Authors:  Ai Junhua; Jin Yun; Wang Zhenzhou; Yang Ling; Luo Ding
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.